The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.
Schizophrenia is a severe mental illness that affects almost 1% of the population worldwide. Even though the etiology of schizophrenia is uncertain, it is believed to be a neurodevelopmental disorder that results from a combination of environmental insults and genetic vulnerabilities. Over the past 20 years, there has been a confluence of evidence from many research disciplines pointing to alterations in excitatory signaling, particularly involving hypofunction of the N-methyl-d-aspartate receptor (NMDAR), as a key contributor to the schizophrenia disease process. This review describes the structure-function relationship of the NMDAR channel and how the glycine modulatory site acts as an important regulator of its activity. In addition, this review highlights the genetic, pharmacologic, and biochemical evidence supporting the hypothesis that NMDAR hypofunction contributes to the pathophysiology of schizophrenia. Finally, this chapter highlights some of the most recent and promising pharmacological strategies that are designed to either, directly or indirectly, augment NMDAR function in an effort to treat the cognitive and negative symptoms of schizophrenia that are not helped by currently available medications.
Harvard Medical School, Boston, MA, United States; McLean Hospital, Belmont, MA, United States. Electronic address: dbalu@mclean.harvard.edu.
D T
DT
Balu
D000818:Animals; D006801:Humans; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D012559:Schizophrenia / Q000503:physiopathology*; D015398:Signal Transduction
D016194:Receptors, N-Methyl-D-Aspartate
Cognition; Glycine; Metabotropic glutamate receptor 5; NMDA receptor; Schizophrenia; Serine racemase; d-serine; α7 Nicotinic acetylcholine receptors